CLF Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Cleveland-Cliffs Inc. is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The stock shows mixed signals, with weak financial performance, insider selling, and a lack of strong positive catalysts. While there is potential for future growth in the steel industry, the current data suggests holding off on investment until clearer positive indicators emerge.
The MACD is negative and contracting, indicating bearish momentum. RSI is neutral at 47.113, showing no clear trend. Moving averages are converging, suggesting indecision in the market. Key support is at 10.067, and resistance is at 11.702. The stock closed at $11, slightly above the pivot point of 10.885, but the overall technical indicators do not suggest a strong buy signal.
The appointment of Ralph 'Mike' Michael III as Lead Independent Director and Edilson Camara as Chairman of the Compensation and Organization Committee may enhance strategic direction and shareholder value. Additionally, the company remains a major player in the North American steel industry, which could benefit from elevated steel prices.
Insider selling has increased significantly by 4686.82% in the last month, and the CEO sold $37.3M worth of shares following a disappointing Q4 report and weak Q1 guidance. Analysts have lowered price targets, citing subdued demand and lackluster financial performance. Hedge funds are neutral, and there is no significant trading trend from institutional investors. Additionally, the company's stretched balance sheet and declining financial metrics pose risks.
In Q4 2025, Cleveland-Cliffs reported a revenue decline of 0.28% YoY to $4.31B. Net income dropped by 45.64% YoY to -$243M, and EPS fell by 52.17% YoY to -$0.44. Gross margin also declined by 24.25% YoY to -4.78%. These metrics indicate significant financial challenges and declining profitability.
Analysts have mixed views, with some maintaining Neutral ratings and lowering price targets due to weak financial performance and subdued demand. GLJ Research has a Sell rating with a $9.42 price target, while Morgan Stanley is more optimistic with an Overweight rating and a $17 price target. However, the overall sentiment leans towards caution, with several downgrades and reduced price targets.
